Navigation Links
Cardium Completes $6.0 Million Financing
Date:11/10/2008

ngina. For more information about Cardium Therapeutics and its businesses, products and therapeutic candidates, please visit http://www.cardiumthx.com or view its 2007 Annual Report at http://www.cardiumthx.com/flash/pdf/CardiumAR07_Book_FINAL.pdf.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that human clinical trials can be conducted and completed in an efficient and successful manner, that partnering opportunities can be successfully achieved and that such opportunities will effectively and efficiently advance commercialization of our products, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that results or trends observed in one clinical study will be reproduced in subsequent studies, that our products or product candidates will prove to be sufficiently safe and effective, that necessary regulatory approvals will be obtained, or that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and therapeutic hypothermia devices and in the conduct of human clinical trials, including the timing,
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. An international first at the CHUM - Promising treatment in regeneration of the myocardium through the use of stem cells
2. Cardium Reports on Recent Highlights and Financial Results
3. Cardiums InnerCool Therapies Unit Announces Australian Distribution Agreement for CoolBlue and Rapid Blue Systems
4. Cardium Announces InnerCools Endovascular Cooling to be Featured on Science Channels Series Cool Stuff: How It Works
5. Eligard(R) six-month formulation successfully completes European approval procedure
6. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
7. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
8. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
9. GSI Securitization Completes Merger and Domicile Transfer
10. Medical Services International Inc. Completes Testing for European Union (EU) Application
11. Inverness Completes Acquisition of Cholestech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)ANAHEIM, Calif., Dec. 4 Pamela Bowen, Chief Information Officer at Crescent Healthcare, was selected as a finalist for the "Chief Innovation Officer" Appy Award for transforming Crescent,s business w
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
(Date:12/4/2009)Case Western Reserve University researchers, from the School of Medicine,s Department of Nutrition, discovered two new metabolic pathways by which products of lipid peroxidation and some drugs of abus
(Date:12/4/2009)Dental tourism is a phenomenon that was started by people that were looking for an alternative to the high price of dental work in the US, Canada, and other countries. In their search for lower priced
(Date:12/4/2009)Move a response to pressure from federal regulators to crack down on abuse of opioid medications , , FRIDAY, Dec. 4 (HealthDay News) -- The makers of 24 different prescription painkillers on F
Breaking Medicine News(10 mins):Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Makers of Powerful Painkillers Present Safety Plans 2
...er company says impact is ,significant and substan...lutant legislation, NEWARK, N.J., July 29 Eric S...th and safety, testified today before,Congress abo...known as CAIR). CAIR would have resulted in dramat...
...ticipants and spectators are reminded to protect t...rays on and off the field, PINELLAS PARK, Fla., J...gerly awaited time to enjoy outdoor sports and act...he summer,-- are conscious of the need to use sunb...
...A, Calif., July 29 On October 30, millions of bre... and loved ones will raise,their glasses in a "Toa... provides an opportunity for anyone,affected by br... cause advocates, thanking supporters, and showing...
...ferers Consider Veins a Cosmetic Issue Despite Exp... Discomfort, CHICAGO, July 29 Varicose veins -...y embarrassed sufferers to cover up, even on,the h...vey, many who suffer from varicose veins aren,t aw...
...Researchers at the University of Minnesota have fo...cognitive impairment in one of four child survivor...of the journal Pediatrics . , Malari...adliest forms of malaria. It only takes one bite f...
... RWSURVEY -- Web-Based Compliance Software Availab...unced the,release of its new web-based compliance ...w.rwsurvey.com ., The web-based software allows u...UA PCI HIPAA Compliance BSA-AML ISO 27001 Cob...
Other Medicine News:Health News:PSEG Supports Quick Congressional Action on Clean Air in Wake of Court's Rescinding of CAIR 2Health News:Transitions Optical Offers Tips on How to Protect Eyes for Outdoor Sports Fans 2Health News:Video: A 'Toast to the Cure' Set for October 30 Breast Cancer Survivors 'Raise Your Glasses' 2Health News:Survey Shows People With Varicose Veins Unaware of Health Risks; Most Never Consider Treatment 2Health News:Survey Shows People With Varicose Veins Unaware of Health Risks; Most Never Consider Treatment 3Health News:Survey Shows People With Varicose Veins Unaware of Health Risks; Most Never Consider Treatment 4Health News:U of M researchers find cerebral malaria may be a major cause of brain injury in African children 2Health News:New Web-Based Compliance Program Released by RiskWatch 2
(Date:12/3/2009)WARRENDALE, Pa., Dec. 3 Radiology imaging leader MEDRAD, Inc. demonstrated PACS* injection-record integration capabilities at the November 2009 Radiology Society of North America in Chicago. The Co
(Date:12/3/2009)HOERSHOLM, Denmark and SAN DIEGO, California, December 3 , - SPC3649 Successfully Inhibits miR-122, a microRNA Important for,Hepatitis C Viral Replication, Thereby Significantly Reducing Hepatiti
(Date:12/3/2009)DURHAM, N.C., Dec. 3 In response to the increasingly critical role of healthcare information technologies in the evolving healthcare delivery system, Duke Medicine has created the Duke Center for Hea
Breaking Medicine Technology:MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5Duke Medicine to Train Healthcare Professionals in Health Informatics 2Duke Medicine to Train Healthcare Professionals in Health Informatics 3Surgeon Approved Pro Athlete Chiropractor Breaks the 2450 Billion Neck Pain Cycle With Launch of Pillo1 First Eco Luxe Neck Pillow 61153 1Surgeon Approved Pro Athlete Chiropractor Breaks the 2450 Billion Neck Pain Cycle With Launch of Pillo1 First Eco Luxe Neck Pillow 61153 2MinuteClinic Celebrates National Nurse Practitioner Week and Recognizes Role of Practitioners in Helping To Close Primary Care Gap 61151 1MinuteClinic Celebrates National Nurse Practitioner Week and Recognizes Role of Practitioners in Helping To Close Primary Care Gap 61151 2MinuteClinic Celebrates National Nurse Practitioner Week and Recognizes Role of Practitioners in Helping To Close Primary Care Gap 61151 3China Sky One Medical Inc Announces Conference Call to Discuss Third Quarter 2009 Results 14794 1China Sky One Medical Inc Announces Conference Call to Discuss Third Quarter 2009 Results 14794 2China Sky One Medical Inc Announces Conference Call to Discuss Third Quarter 2009 Results 14794 3
...ternational Conference of the American ... Forest Laboratories, Inc. and,Laboratorios Almir...al,trials assessing the efficacy and safety of acl...chronic obstructive pulmonary disease (COPD).,Data...the properties of,aclidinium were also presented a...
...ine and Synta,Pharmaceuticals Corp. (Nasdaq: SNTA... for elesclomol (formerly STA-4783), an investigat...c melanoma. A retrospective analysis,showed that s...elesclomol,and paclitaxel who had not previously r...nt improvement in progression-free survival (PFS),...
Other Medicine Technology:Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 2Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 3Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 4Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 5Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 2Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 3Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 4Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 5Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 6Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 7
MedLook 3.0
... Manager and Collections Administrator has a maxim...billing models and personalized paper or electroni...ty to facilitate rebilling, ledger notes, follow-u...en Collections Worksheet and efficient collection ...
...ware Associates medical billing and practice manag...ronically, while providing your practice with acco...e interface allows you to see insurance payments, ...ntage of services rendered. You can break these nu...
Infinity Amylase CNPG3 (Liquid)
Medicine Products: